TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03949283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy
Description: Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab.
Study: NCT03375996

Intervention type: DRUG
Intervention: cyclopentolate 0.5% eye drops
Description: cyclopentolate 0.5% eye drops and measurement of the pupillary mydriasis (dilatation)
Study: NCT04372563

Intervention type: OTHER
Intervention: aortic prosthetics
Description: aortic prosthetics

Intervention type: OTHER
Intervention: aortic prosthetics
Description: aortic prosthetics

Intervention type: OTHER
Intervention: aortic prosthetics
Description: aortic prosthetics
Study: NCT01027910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-24781
Description: Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered intravenously on Day 4 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered intravenously on Day 4 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2
Study: NCT03096548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Safety Ink! Program
Description: The intervention will be comprised of an online skin cancer prevention training for all tattoo artists of participating studios. The training will include skin cancer rates and risk factors, tattoo rates, recommendations for sun protection practices, a rationale for the relationship of tattoo care and sun safety, and recommended communication strategies for artists to communicate skin cancer prevention to their clients. Additional printed materials (tip-card for clients, posters) to be displayed in tattoo studios, a Sun Safety Ink! website, and social media messages for tattoo studios' Facebook and Pinterest pages will be provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Studios and artists in this attention control group will not receive the Sun Safety Ink! program. They will continue to provide standard aftercare instructions to clients. The program will be provided to them at the end of the study.
Study: NCT04365322

Intervention type: OTHER
Intervention: Additional biological samples
Description: Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.

Intervention type: OTHER
Intervention: Additional biological samples
Description: Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.

Intervention type: OTHER
Intervention: Additional biological samples
Description: Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
Study: NCT04297046

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCA (patient controlled analgesia)
Description: Intravenous Patient-Controlled Analgesia was used for postoperative pain control with a bolus dose of 25 mg Tramadol and a lockout interval of 20 min. The pain was evaluated at different times after the operation, both at rest and movement (Dynamic VAS) at the 0., 2., 6., 12. hours and 24h later. All patients received 1 g iv paracetamol 8 hourly intervals regularly. 75 mg im diclofenac sodium was given as rescue analgesic.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCA (patient controlled analgesia)
Description: Intravenous Patient-Controlled Analgesia was used for postoperative pain control with a bolus dose of 25 mg Tramadol and a lockout interval of 20 min. The pain was evaluated at different times after the operation, both at rest and movement (Dynamic VAS) at the 0., 2., 6., 12. hours and 24h later. All patients received 1 g iv paracetamol 8 hourly intervals regularly. 75 mg im diclofenac sodium was given as rescue analgesic.
Study: NCT00352534

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Patients undergo radiotherapy
Study: NCT01928264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Study: NCT01235754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal testosterone gel 1%
Description: 300 mcg once daily transdermal testosterone gel 1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: once daily transdermal placebo gel
Study: NCT00707239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline
Description: An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline
Description: An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imipenem/cilastatin
Description: Imipenem/cilastatin 1g intravenous (IV) will be administered approximately every 8 hours, for up to 14 consecutive days. In addition vancomycin 15 mg/kg IV approximately every 12 hours (q12h), an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and ceftazidime placebo will be given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
Study: NCT02877901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long acting tolterodine 4 mg
Description: receive one tablet at bed time for 4 weeks
Study: NCT01256645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood transfusion
Description: application of single units of red blood cell transfusions
Study: NCT04214808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-208
Description: Dutasteride 0.2mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-208
Description: Dutasteride 0.2mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avodart Soft Capsule 0.5mg
Description: Dutasteride 0.5mg
Study: NCT02864953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB093
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT03356834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide(TAF)
Description: 25 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate(TDF)
Description: 300 mg tablet administered orally once daily
Study: NCT04024722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro Fertilization
Description: Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro Fertilization
Description: Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.
Study: NCT03944798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequency: Every 3 Months
Description: every 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequency: Every 3 Months
Description: every 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frequency: Every 6 Months
Description: every 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequency: Every 6 Months
Description: every 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imaging Modality: Chest Radiograph (CXR)
Description: Chest radiograph (CXR)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Modality: Chest Radiograph (CXR)
Description: Chest radiograph (CXR)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Modality: Chest CT
Description: Chest computed tomography (CT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Modality: Chest CT
Description: Chest computed tomography (CT)
Study: NCT02118818

Intervention type: GENETIC
Intervention: Next generation sequencing
Description: There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.

Intervention type: GENETIC
Intervention: Next generation sequencing
Description: There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
Study: NCT04214808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avodart Soft Capsule 0.5mg
Description: Dutasteride 0.5mg
Study: NCT01665014

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total marrow irradiation
Description: Mobilization of stem cells with the use of cytarabine 1.6 g/m2 followed by filgrastim 480 ug/d. Conditioning for the 1st autoHSCT: total marrow irradiation 4 Gy on days -3,-2,-1 (total 12 Gy). Conditioning for 2nd autoHSCT performed 3-4 months after the 1st one: melphalan 100 mg/m2 on days -2,-3 (total 200 mg/m2)
Study: NCT04644770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-69086420
Description: Participants will receive IV injection of JNJ-69086420.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-69086420
Description: Participants will receive IV injection of JNJ-69086420.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-69086420
Description: Participants will receive IV injection of JNJ-69086420.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-69086420
Description: Participants will receive IV injection of JNJ-69086420.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-78278343
Description: Participants will receive IV infusion of JNJ-78278343.
Study: NCT03199495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: acupuncture needle with TENS device

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electroacupuncture
Description: acupuncture needle with TENS device
Study: NCT02543229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: OPT-302 will be administered by intravitreal injection once every month for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: OPT-302 will be administered by intravitreal injection once every month for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: OPT-302 will be administered by intravitreal injection once every month for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: OPT-302 will be administered by intravitreal injection once every month for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: OPT-302 will be administered by intravitreal injection once every month for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: OPT-302 will be administered by intravitreal injection once every month for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis™
Description: Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis™
Description: Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis™
Description: Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis™
Description: Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
Study: NCT02877901

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet at bed time
Study: NCT03612713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Medication First
Description: Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo First
Description: Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
Study: NCT04654286

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve transfer procedure
Description: 1. Identification of potential donor nerves: phrenic nerve, accessory nerve, intercostal nerve, motor branch nerve innervating long head of triceps muscle, motor branch of ulnar nerve innervating flexor carpi ulnaris (FCU) muscle, and motor branch of median nerve innervating flexor carpi radialis (FCR) muscle.~2. Donor nerve is checked for its viability with an electric stimulator during surgery~3. Viable donor nerve is dissected, transferred to the recipient area, and sutured with end-to-end anastomosis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve transfer with HAM-AdMSC composite wrapping
Description: When the nerve transfer procedure is finished, the end-to-end anastomosis is wrapped by a composite consisted of human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC)
Study: NCT04247646

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
Study: NCT00140101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZoMaxx™ Drug-Eluting Coronary Stent System
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study: NCT03212443

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular nerve- axillary nerve block combination
Description: In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Subacromial infiltration
Description: In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
Study: NCT01119352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7687
Description: Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension, once daily. Totally 8 doses
Study: NCT02258399

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Moderate intensity exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: Breakfast consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: Breakfast consumption
Study: NCT00486642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study: NCT01845441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Precedex will be given to randomized subjects in thi study to evaluate its efficacy in maintaining optimal sedation and preserving neurological exam.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
Study: NCT01459523

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal placement
Description: Subjects assigned to this group will have their perineural catheter placed in a proximal position (higher up in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
Study: NCT00486642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01563029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate
Description: current asthma medicine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate
Description: current asthma medicine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate
Description: current asthma medicine
Study: NCT00352534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound
Study: NCT01563029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Fluticasone propionate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00002879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine
Study: NCT01459523

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short axis ultrasound
Description: Subjects assigned to this group will have the target nerve or plexus identified in short axis (cross-section) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long axis
Description: Subjects assigned to this group will have the target nerve or plexus identified in long axis (longitudinal) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal placement
Description: Subjects assigned to this group will have their perineural catheter placed in a distal position (further down in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
Study: NCT02029027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GYNEFFIK(R)
Description: Vaginal electro-stimulation medical device

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation